Table 2 Information on the basic characteristics of the included studies
Authors | Year | TB-1 | Type of budding | Stage of tumor | Neoadjuvant therapy | Interval (weeks) | Pathology source | Recognition methods | |
|---|---|---|---|---|---|---|---|---|---|
TB-1 | TB-0 | ||||||||
C. Du | 2012 |  ≥ 10 | PTB | ypT1–2:ypT3–4 = 13:23, ypN0:ypN +  = 16:20 | ypT1–2:ypT3–4 = 20:28, ypN0:ypN +  = 34:14 | nRT | 2–3 | Postoperative specimens | H&E/IHC |
M. Huebner | 2012 |  ≥ 10 | PTB | yp0 = 39; yp1 = 14; yp2 = 25; yp3 = 144; yp4 = 15 | CRT | 6–8 | Postoperative specimens | H&E | |
A. C. Rogers | 2013 |  ≥ 1 | ITB | ypT0–1 = 0; ypT2 = 4; ypT3 = 11; ypT4 = 3 | ypT0 = 10; ypT1 = 6; ypT2 = 16; ypT3 = 33; ypT4 = 6 | CRT | 6–8 | Pretreatment biopsies | H&E |
J. W. Huh | 2016 | NA | NA | II 26; III 183 | CRT | 6–8 | Pretreatment biopsies | IHC | |
T. Jäger | 2018 |  ≥ 5 | PTB | pT0 = 0; pT1 = 2; pT2 = 17; pT3 = 57; pT4 = 5, pN −  = 52; pN +  = 29 | pT0 = 16; pT1 = 5; pT2 = 19; pT3 = 7; pT4 = 0, pN −  = 40; pN +  = 7 | CRT | 90 days | Postoperative specimens | H&E |
M. Swets | 2018 |  ≥ 5 | PTB | II = 29; III = 192 | nRT | NA | Postoperative specimens | H&E | |
A. Demir | 2019 |  ≥ 10 | PTB | NA | CRT | 8–12 | Postoperative specimens | H&E | |
J. W. Huh | 2019 | NA | NA | pT0 = 154; pT1 = 29; pT2 = 165; pT3 = 278; pT4 = 13, pN −  = 450; pN +  = 189 | CRT | 6–8 | Postoperative specimens | NA | |
I. Trotsyuk | 2019 |  ≥ 5 | PTB&ITB | ypT0–1 = 0; ypT2 = 6; ypT3 = 26; ypT4 = 6, ypN −  = 12; ypN +  = 26 | ypT0–1 = 10; ypT2 = 16; ypT3 = 25; ypT4 = 4, ypN −  = 40; ypN +  = 25 | CRT | 4–6 | Postoperative specimens | H&E/IHC |
L. Farchoukh | 2021 |  ≥ 2 | ITB | 0–I = 49, II–III = 68 | CRT/TNT | NA | Pretreatment biopsies | H&E | |
J. K. Shin | 2021 |  ≥ 5 | PTB | ypTI = 26; ypTII = 72; ypTIII = 111 | ypTI = 24; ypTII = 73; ypTIII = 112 | CRT | 6–8 | Postoperative specimens | H&E |